RxDoctor Payments Data

James Burleson, MD

Family Medicine · Snyder, TXNPI 1639134430

Payments from drug & device makers

$744in general payments, 2019–2025

Across 47 payments — averaging $15.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$89
  • Novo Nordisk$81
  • AbbVie$67
  • Medtronic$67
  • Lilly USA, LLC$66
  • Smith+Nephew$55
  • plus $320 from 11 others

What the payments were for

  • Food & beverage$744100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$744 in reported general payments places this provider in the 55th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$9,569
Medicare patients
36
Services billed
115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban149$90,890
OzempicSemaglutide68$69,308
JardianceEmpagliflozin72$43,351
FarxigaDapagliflozin Propanediol65$41,165
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$29,744
MounjaroTirzepatide23$24,112
XareltoRivaroxaban30$23,524
RybelsusSemaglutide25$23,231
TrulicityDulaglutide21$19,287
JanuviaSitagliptin Phosphate27$19,066
LinzessLinaclotide29$14,729
Breo ElliptaFluticasone/Vilanterol29$11,272
TradjentaLinagliptin19$9,668
MyrbetriqMirabegron21$8,940
EntrestoSacubitril/Valsartan12$8,264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Levemir$81$94,671115 claims
PfizerEliquis$52$90,890149 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$28$44,52889 claims
Lilly USA, LLCMounjaro, Trulicity$66$43,39944 claims
AstraZenecaFarxiga$89$41,16565 claims
Johnson & JohnsonXarelto$54$23,52430 claims
AbbVieLinzess$67$14,72929 claims
NovartisEntresto$39$8,26412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Snyder

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →